The following is a summary of the Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Apyx Medical Corporation reported a 16% year-over-year increase in total revenue to $14.7 million in Q4 2023.

• The company's gross profit for Q4 2023 stood at $8.9 million, at a 60.9% gross margin.

• Advanced Energy equipment sales rose by 15% year-over-year to $12.1 million, contributing significantly to total revenue.

• However, an increase in operating expenses of 4% led to a net loss increase of 59% to $9.6 million.

• The company's gross margins declined slightly due to year-end inventory cleanup and changes in product and customer mix.

• For 2024, Apyx expects total revenue to range between $49.7 million and $52.9 million with a projected gross margin of 61%.

Business Progress:

• Apyx successfully launched the Renuvion Micro Handpiece, which received positive initial feedback.

• Sales of handpieces showed strong growth within the U.S, up by over 35% year-over-year.

• Internationally, Apyx reported a robust increase in generator sales by over 80% year-over-year.

• In 2023, Apyx achieved its focus areas of securing additional clinical use indications, enhancing the portfolio, expanding clinical evidence, and managing expenses for profitability.

• In 2024, the company aims to secure new customer adoption, particularly by simplifying the capital purchasing process.

• The recently launched Micro Handpiece and Apyx One technology are key to the company's growth strategy, with emphasis on handpiece growth in 2024 and beyond.

• The company continues international expansion efforts, including securing clearances in large cosmetic markets like Korea and China. It also aims to foster customer awareness through direct-to-consumer initiatives.

More details: Apyx Medical IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.